Wellington Management Group LLP Invests $922,000 in Aquestive Therapeutics, Inc. (NASDAQ:AQST)

Wellington Management Group LLP bought a new stake in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 185,191 shares of the company's stock, valued at approximately $922,000. Wellington Management Group LLP owned approximately 0.20% of Aquestive Therapeutics as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. State Street Corp increased its holdings in Aquestive Therapeutics by 52.1% during the 3rd quarter. State Street Corp now owns 1,496,739 shares of the company's stock worth $7,454,000 after acquiring an additional 512,682 shares during the period. Blue Owl Capital Holdings LP raised its position in shares of Aquestive Therapeutics by 30.3% in the second quarter. Blue Owl Capital Holdings LP now owns 1,140,000 shares of the company's stock worth $2,964,000 after buying an additional 265,000 shares in the last quarter. Janney Montgomery Scott LLC raised its position in shares of Aquestive Therapeutics by 4.9% in the third quarter. Janney Montgomery Scott LLC now owns 923,285 shares of the company's stock worth $4,598,000 after buying an additional 42,800 shares in the last quarter. Bank of New York Mellon Corp purchased a new position in Aquestive Therapeutics during the second quarter worth about $594,000. Finally, Charles Schwab Investment Management Inc. grew its position in Aquestive Therapeutics by 4.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 203,540 shares of the company's stock worth $1,014,000 after buying an additional 9,268 shares in the last quarter. Hedge funds and other institutional investors own 32.45% of the company's stock.

Aquestive Therapeutics Price Performance

NASDAQ AQST traded up $0.01 on Friday, reaching $3.65. 1,344,092 shares of the company's stock traded hands, compared to its average volume of 1,739,676. The stock has a market cap of $332.80 million, a PE ratio of -8.11 and a beta of 2.62. Aquestive Therapeutics, Inc. has a 12 month low of $1.84 and a 12 month high of $6.23. The stock has a 50-day simple moving average of $4.74 and a 200 day simple moving average of $4.06.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last posted its quarterly earnings results on Monday, November 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The business had revenue of $13.54 million for the quarter, compared to analyst estimates of $12.69 million. During the same period last year, the firm posted ($0.03) EPS. As a group, analysts anticipate that Aquestive Therapeutics, Inc. will post -0.47 EPS for the current year.

Analysts Set New Price Targets

AQST has been the subject of a number of research analyst reports. Leerink Partners lifted their price target on Aquestive Therapeutics from $12.00 to $13.00 and gave the company an "outperform" rating in a research report on Friday, October 25th. JMP Securities reiterated a "market outperform" rating and set a $9.00 target price on shares of Aquestive Therapeutics in a research report on Tuesday, October 8th. Cantor Fitzgerald started coverage on shares of Aquestive Therapeutics in a research note on Tuesday. They issued an "overweight" rating and a $17.00 price target for the company. Finally, HC Wainwright restated a "buy" rating and set a $10.00 price objective on shares of Aquestive Therapeutics in a research report on Friday. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Aquestive Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $11.00.

Aquestive Therapeutics Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.